Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines
- 1 May 2018
- journal article
- research article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 37 (5) , 724-731
Abstract
Precision medicines can benefit patients by increasing the probability of a successful treatment response in selected patient populations. The potential for more immediate signals of efficacy during clinical trials suggests such medicines will reach the market more rapidly than traditional drugs will. Using data from the Food and Drug Administration (FDA), we examined the regulatory review and pivotal trial characteristics of precision medicines. We found that in the period January 2013–June 2017, precision medicines were developed and reviewed almost two years faster than nonprecision medicines. In addition, approximately 48 percent of the precision medicines in our study qualified for the FDA’s breakthrough therapy designation. Precision medicines were also approved based on fewer pivotal trials with fewer patients, and the trials were less likely to be randomized, blinded, or controlled with either an active or placebo comparator.Keywords
This publication has 25 references indexed in Scilit:
- Precision medicine in oncology drug development: a pharma perspectiveDrug Discovery Today, 2015
- The changing landscape of phase I trials in oncologyNature Reviews Clinical Oncology, 2015
- A New Initiative on Precision MedicineNew England Journal of Medicine, 2015
- Biomarker enrichment strategies: matching trial design to biomarker credentialsNature Reviews Clinical Oncology, 2013
- Personalized Genomic Medicine and the Rhetoric of EmpowermentHastings Center Report, 2012
- Preparing for Precision MedicineNew England Journal of Medicine, 2012
- Has the revolution arrived?Nature, 2010
- Paradigms and the rise (or fall?) of molecular biologyNature Biotechnology, 1997
- Ancient Genomes, Wise Bodies, Unhealthy People: Limits of a Genetic Paradigm in Biology and MedicinePerspectives in Biology and Medicine, 1993
- DRUG REACTIONS, ENZYMES, AND BIOCHEMICAL GENETICSJAMA, 1957